Knowing many sufferers of the current flu bout, it is timely to report positive preliminary results in the Phase 2b trials of the Universal Flu vaccine from Israel’s BiondVax.  And thanks to a $2.8 million investment (see Jan 15), BiondVax is to “proceed confidently into Phase 3 as planned.”

http://www.biondvax.com/2016/11/biondvax-phase-2b-trial-preliminary-safety-results-the-universal-flu-vaccine-candidate-is-safe-and-well-tolerated/